Moleculin Biotech's Q1 2025 earnings call highlights Phase 3 MIRACLE trial progress, EU regulatory signoff, patient enrollment milestones, and funding needs.

Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters ...

Absci Corp (ABSI) reports increased R&D expenses and low revenue, but showcases promising clinical advancements and a robust cash position.

Columbia University, the Company's collaboration partner for pre-clinical development, granted Silo an exclusive global ...

The $25 million lab will handle research and development as well as quality testing for Civica’s nearby pharmaceutical plant ...

Q1 2025 Earnings Call May 14, 2025 8:30 AM ETCompany ParticipantsBrian Ritchie - Investor RelationsDikla Czaczkes Akselbrad ...

About 15 percent of USDA’s workforce has accepted the Trump administration’s buyout to leave the agency, including more than ...

We recently published a list of 12 Best Quantum Computing Stocks to Invest in Now. In this article, we are going to take a ...

Patient dosing has commenced, and the initial data readout is on track for the second half of 2025. For more information about the MIRACLE trial, visit clinicaltrials.gov and reference identifier ...

Cash and Cash Equivalents: As of March 31, 2025, Kalaris had cash and cash equivalents of $101.0 million, compared with cash and cash equivalents of $1.6 million as of December 31, 2024. The increase ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode ...